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Background: Traumatic brain injury (TBI) induces secondary injury mechanisms, including dynamic interplay
between ischemic, inflammatory and cytotoxic processes. We recently reported that administration of ATB-346
(2-(6-methoxynapthalen- 2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester), a hydrogen sulfide-releasing
cyclooxygenase inhibitor, showed marked beneficial effects in an animal model of spinal cord injury, significantly
enhancing recovery of motor function and reducing the secondary inflammation and tissue injury.
Methods: Here we evaluated the neuroprotective potential of ATB-346, a hydrogen sulfide-releasing derivative of
naproxen, using the controlled cortical impact (CCI) injury model in mice, one of the most common models of TBI.
Moreover, the aim of the present study was to carefully investigate molecular pathways and subtypes of glial cells
involved in the protective effect of ATB-346 on inflammatory reaction associated with an experimental model of
TBI. In these studies, TBI was induced in mice by CCI and mice were orally administered ATB-346, naproxen (both at
30 μmol/kg) or vehicle (dimethylsulfoxide:1% carboxymethylcellulose [5:95] suspension) one and six hours after
brain trauma and once daily for 10 days.
Results: Results revealed that ATB-346 attenuated TBI-induced brain edema, suppressed TBI-induced neural cell
death and improved neurological function. ATB-346 also significantly reduced the severity of inflammation and
restored neurotrophic factors that characterized the secondary events of TBI.
Conclusions: These data demonstrate that ATB-346 can be efficacious in a TBI animal model by reducing the
secondary inflammation and tissue injury. Therefore, ATB-346 could represent an interesting approach for the
management of secondary damage following CNS diseases, counteracting behavioral changes and inflammatory
process.
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Traumatic brain injury (TBI) is a growing public health
concern worldwide. There are over 1.35 million emergency
room visits and 275,000 hospitalizations for nonfatal TBI
each year in the United States, and approximately 40% of
these individuals suffer from long-term disability due to
their injury [1]. The pathophysiology of TBI can be divided
into primary and secondary brain injury [2]. Primary injury
results from the direct, physical brain trauma with tissue
distortion, shearing, vascular injury and cell destruction
probably related to rotational acceleration and deceleration
inertial forces. Secondary brain injury is related to destruc-
tive inflammation and biochemical changes. Secondary in-
jury onsets within minutes of primary injury, may last for
several days and contributes to final outcome [3]. Primary
and secondary brain injuries induce cerebral edema and
bleeding. During secondary neuronal injury, healthy neu-
rons around the injury site progressively degenerate, even-
tually leading to more serious clinical symptoms. Therefore,
secondary neuronal injury plays a key role in the severity of
insult and subsequent clinical prognosis.
Non-steroidal anti-inflammatory drugs (NSAIDs) are
among the most commonly used anti-inflammatory drugs,
but their use is associated with significant, sometimes life-
threatening, adverse effects, particularly in the gastrointes-
tinal (GI) tract [4]. Along with nitric oxide (•NO) and car-
bon monoxide (CO), hydrogen sulfide (H2S) is regarded as
an important gasotransmitter and endogenous neuromo-
dulator, drawing increasing attention in the literature.
Traditional neurotransmitters bind and activate mem-
brane receptors, while gasotransmitters can freely diffuse
to adjacent cells and directly bind to their target proteins
to modify biological functions. Therefore, H2S is a physio-
logic gasotransmitter as important as •NO and CO. In the
past decade, increasing evidence shows that H2S plays
multiple roles in the CNS under physiological and patho-
logical states. H2S is produced in various parts of the body
including the heart [5], the cardiovascular system [6] and
the central nervous system (CNS) [7]. With respect to the
CNS, H2S has been reported to exert neuroprotective and
neuromodulatory effects [8,9]. Thus, H2S has recently
been exploited in the design of novel NSAID derivatives
that exhibit little, if any, side effects in the GI tract, despite
producing suppression of prostaglandin synthesis and
reduction of inflammation at least as effectively as the
parent NSAID [10]. Recently, beneficial effects of an H2S-
releasing derivative of naproxen have been shown in an
animal model of spinal cord injury (SCI), significantly en-
hancing recovery of motor function, possibly by reducing
the secondary inflammation and tissue injury that charac-
terizes this model. The combination of inhibition of cyclo-
oxygenase [11] and delivery of H2S may offer a promising
alternative to existing therapies for traumatic injury [12].
On the basis of these data, H2S could have an importantrole in reducing inflammatory processes and tissue dam-
age post-brain trauma. Therefore, in the current study we
evaluated ATB-346, a novel H2S-releasing derivative of na-
proxen, for neuroprotective properties in experimental
murine TBI using controlled cortical impact injury (CCI),
a model of focal brain injury. Moreover, the aim of the
present study was to carefully investigate molecular path-
ways and subtypes of glial cells involved in the protective
effect of ATB-346 on inflammatory reaction associated
with an experimental model of TBI. In particular, our at-
tention shifts to post-injury recovery of motor function,
reduction of infarct area and of brain tissue inflammation
after TBI.Methods
Animals
Male CD1 mice (25 to 30 g, Harlan, Milan, Italy), aged be-
tween 10 and 12 weeks, were used for all studies. Mice
were housed in individual cages (five per cage) and main-
tained under a 12:12 hour light/dark cycle at 21 ± 1°C and
50 ± 5% humidity. Standard laboratory diet and tap water
were available ad libitum. The study was approved by the
University of Messina Review Board for the care of ani-
mals. Animal care was in compliance with Italian regula-
tions on protection of animals used for experimental and
other scientific purposes (Ministerial Decree 16192) as
well as with the Council Regulation (EEC) (Official Journal
of the European Union L 358/1 12/18/1986).Controlled cortical impact experimental traumatic brain
injury
TBI was induced in mice by a controlled cortical impactor.
The mice were anesthetized under intraperitoneal keta-
mine and xylazine (2.6/0.16 mg/kg of body weight, respect-
ively). A craniotomy was made in the right hemisphere,
encompassing bregma and lambda, and between the sagit-
tal suture and the coronal ridge, with a Micro motor hand
piece and drill (UGO Basile SRL, Comerio Varese, Italy).
The resulting bone flap was removed and the craniotomy
enlarged further with cranial rongeurs (New Adalat Garh,
Roras Road, Pakistan). A cortical contusion was produced
on the exposed cortex using the controlled impactor de-
vice Impact OneTM Stereotaxic impactor for CCI (Leica,
Milan, Italy). Briefly, the impacting shaft was extended,
and the impact tip was centered and lowered over the cra-
niotomy site until it touched the dura mater. Then, the rod
was retracted and the impact tip was advanced farther to
produce a brain injury of moderate severity for mice (tip
diameter: 4 mm; cortical contusion depth: 3 mm; impact
velocity: 1.5 m/sec). Immediately after injury, the skin inci-
sion was closed with nylon sutures, and 2% lidocaine jelly
was applied to the lesion site to minimize any possible
discomfort.
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ATB-346 (2-(6-methoxynapthalen-2-yl)-propionic acid 4-
thiocarbamoyl phenyl ester) is a derivative of naproxen,
which includes a H2S-releasing moiety referred to hereafter
as ‘TBZ’ (4-hydroxythiobenzamide) [13]. ATB-346, TBZ
and naproxen were prepared freshly each day as suspen-
sions in dimethylsulfoxide:1% carboxymethylcellulose (5:95).
Prior to beginning these experiments, a pilot study
was performed to confirm the equipotency of naproxen
and ATB-346 in suppressing cyclooxygenase at the dose
selected. At 30 μmol/kg (oral administration), naproxen
and ATB-346 equally suppressed gastric (prostaglandin
E2) PGE2 synthesis (by more than 90%) and whole blood
thromboxane synthesis ( by more than 95%). This level
of inhibition was evident within 15 minutes and per-
sisted for at least 12 hours after drug administration.
TBZ had no effect on gastric PGE2 synthesis or whole
blood thromboxane synthesis.
Experimental groups
Mice were randomly allocated into one of five groups. In
the TBI + vehicle group, mice were subjected to TBI and
received the vehicle for TBZ, naproxen and ATB-34
(dimethylsulfoxide:1% carboxymethylcellulose) (orally), at
one and six hours after brain trauma (N = 20). The TBZ
group was the same as the TBI + vehicle group, but mice
were administered TBZ only (30 μmol/kg, orally), at one
and six hours after brain trauma (N = 20). The naproxen
group was the same as the TBI + vehicle group, but mice
were administered naproxen only (30 μmol/kg, orally), at
one and six hours after brain trauma (N = 20). The ATB-
346 group was the same as the TBI + vehicle group, but
mice were administered ATB-346 only (30 μmol/kg, or-
ally), at one and six hours after brain trauma (N = 20). In
the sham + vehicle group mice were subjected to identical
surgical procedures, except for TBI, and were kept under
anesthesia for the duration of the experiment (N = 20).
As described below, mice were sacrificed at 24 hours
after TBI in order to evaluate the following parameters:
2,3,5-triphenyltetrazolium chloride (TTC) staining (N =
four out of 20 for each group) [14]; histology analysis
(N = three out of 20 for each group) and Tumor necrosis
factor (TNF)α, Interleukin (IL)-1β, Glial fibrillary acidic
protein (GFAP) and Ionized calcium binding adaptor
molecule (Iba)1 immunofluorescence (N = three out of
20 for each group) [14]; Western blot analysis (N = five
out of 20 for each group) and RT-PCR analysis for Glial
cell-Derived Neurotrophic Factor (GDNF), Nerve Growth
Factor (NGF) and Vascular Endothelial Growth Factor
(VEGF) levels (N = five out of 20 for each group). In a
separate set of experiments, another 10 animals from
each group were observed after TBI in order to evaluate
the behavioral testing. Several recent results illustrate
the importance of initiating therapeutic interventions assoon as possible following TBI, preferably within four
hours post-injury, to achieve the best possible neuropro-
tective effect [15].
Behavioural testing
Mice with TBI display motor and cognitive deficits.
Thus, the present behavioural tests involved analyses of
motor asymmetry (elevated biased swing test (EBST)
and rotarod test). Training for the rotarod test was initi-
ated at one week. Before the CCI injury, whereas no
training was required for the EBST. The retard treadmill
(Accuscan, Inc., Columbus, Ohio, United States) pro-
vided a motor balance and coordination assessment.
Data were generated by averaging the scores (total time
spent on treadmill divided by five trials) for each animal
during training and testing days. Each animal was placed
in a neutral position on a cylinder (3 cm and 1 cm diam-
eter for rats and mice, respectively) then the rod was ro-
tated with the speed accelerated linearly from 0 to 24
rpm within 60 seconds, and the time spent on the retard
was recorded automatically. The maximum score given
to an animal was fixed to 60. For training, animals were
given five trials each day and declared having reached
the criterion when they scored 60 in three consecutive
trials. For testing, animals were given three trials and the
average score of these three trials was used as the indi-
vidual rotarod score. The EBST provided a motor asym-
metry parameter and involved handling the animal by its
tail and recording the direction of the biased body
swings. The EBST consisted of 20 trials with the number
of swings ipsilateral and contralateral to the injured
hemisphere recorded and expressed in percentage to de-
termine the biased swing activity.
Quantification of infarct volume
Mice were anesthetized with ketamine and decapitated.
Their brains were carefully removed. The brains were cut
into five coronal slices of 2-mm thickness. Slices were in-
cubated in a 2% solution of TTC at 37°C for 30 minutes
and immersion fixed in 10% buffered formalin solution.
TTC stains the viable brain tissue red while infracted tis-
sue remains unstained [16,17]. For quantification of
infracted area and volumes, the brain slices were photo-
graphed using a digital camera (HP Photosmart R707,
Milan, Italy) and then image analysis was performed on a
personal computer with an image analysis software pro-
gram (using ImageJ for Windows (Institute of Mental
Health, Maryland, USA). To compensate for the effect of
brain edema the corrected infarct volume was calculated
as previously described in detail [18]:
Corrected infarct area ¼ left hemisphere area ‐ rightð
hemisphere area ‐ infarct areaÞ:
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farct volume was calculated by summing the infarct area
in each slice and multiplying it by slice thickness (2 mm).
Tissue processing and histology
Coronal sections of 5-μm thickness were sectioned from
the perilesional brain area of each animal and were evalu-
ated by an experienced histopathologist. Damaged neu-
rons were counted and the histopathologic changes of the
grey matter were scored on a six-point scale [19]: 0, no
lesion observed; 1, grey matter contained one to five eo-
sinophilic neurons; 2, grey matter contained five to 10 eo-
sinophilic neurons; 3, grey matter contained more than 10
eosinophilic neurons; 4, small infarction (less than one
third of the grey matter area); 5, moderate infarction (one
third to one half of the grey matter area); 6, large infarc-
tion (more than half of the grey matter area). The scores
from all the sections of each brain were averaged to give a
final score for individual mice. All the histological studies
were performed in a blinded fashion.
Western blot analyses
Cytosolic and nuclear extracts were prepared as previ-
ously described [20], with slight modifications. The ipsi-
lateral hemisphere after injury from each mouse was
suspended in extraction Buffer A containing protease in-
hibitors, homogenized for two minutes, then centrifuged
at 1,000 × g for 10 minutes at 4°C. Supernatants con-
tained the cytosolic fraction. The pellets, containing
enriched nuclei, were resuspended in Buffer B contain-
ing 1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl
pH 7.4, 1 mM, ethylene glycol tetraacetic acid (EGTA), 1
mM, ethylenediaminetetraacetic acid (EDTA), 0.2 mM
phenylmethanesulfonylfluoride (PMSF) and protease in-
hibitors. After centrifugation for 30 minutes at 15,000 ×
g at 4°C, the supernatants containing the nuclear protein
were stored at −80°C for further analysis. The levels of
inducible nitric oxide synthase (iNOS), cyclooxygenase
(COX)-2, endothelial nitric oxide synthase (eNOS) and
IκBα were quantified in cytosolic fractions. NFκBp65
was quantified in nuclear fractions from brain tissue col-
lected 24 hours after TBI. The filters were probed with
specific Abs anti-iNOS (1:1,000; BD Biosciences, Milan,
Italy), anti-COX-2 (1:1,000; Cayman Chemicals, Tallinn
Estonia), anti-eNOS (1:1000; BD Biosciences, Milan,
Italy), anti-NFκBp65 (1:500; Santa Cruz Biotechnology,
Heidelberg, Germany) and anti-IκBα antibody (1:500;
Santa Cruz Biotechnology, Heidelberg, Germany) at 4°C
overnight in 1 × PBS, 5% (w/v), non-fat dried milk and
0.1% Tween-20 (PMT). Membranes were incubated with
peroxidase-conjugated bovine anti-mouse IgG secondary
antibody or peroxidase-conjugated goat anti-rabbit IgG
(1:2,000; Jackson ImmunoResearch, West Grove, PA,
USA) for one hour at room temperature. To ascertainthat blots were loaded with equal amounts of protein ly-
sates, they were also incubated in the presence of the anti-
body against β-actin or lamin A/C (1:5,000; Santa Cruz
Biotechnology, Heidelberg, Germany). The signals were
detected with enhanced a chemiluminescence detection
system reagent according to manufacturer’s instruction
(Super Signal West Pico Chemiluminescent Substrate,
Pierce Thermo Scientific, Rockford, IL. USA). The relative
expression of the protein bands of IκBα (approximately 37
kDa), NFκB (approximately 65 kDa), eNOS (approximately
140 kDa), iNOS (approximately 130 kDa) and COX-2 (ap-
proximately 72 kDa) were quantified by densitometry with
Gel Logic 200 PRO software (GE Healthcare, Milwaukee,
Wisconsin, USA) and standardized to β-actin and lamin
A/C levels. Images of blot signals were imported to ana-
lysis software Image Quant TL Software, version 2003 (GE
Healthcare, Milwaukee, Wisconsin, USA). A preparation
of commercially available molecular weight 10 to 250 kDa
was used to define molecular weight positions, and as
reference concentrations for each molecular weight.
Reverse transcription polymerase chain reaction
Total RNA, from contused brain tissue at the impact site
after injury, was extracted by a modified method [21],
using TRIzol™ Reagent (Life Technologies, Milan, Italy) ac-
cording to the manufacturer’s instructions. Reverse tran-
scription was performed by a standard procedure using 2
μg of total RNA. After reverse transcription, 1 μl of reverse
transcriptase (RT) products were diluted in 24 μl of PCR
mix, to give a final concentration of 50 U ml −1 of Taq
DNA polymerase (Life Technologies, Milan, Italy), 10 μm
of 5′ and 3′ primers, 10 mM of each deoxynucleotide tri-
phosphates (dNTP), 50 mM MgCl2 and 10 ×NH4 buffer.
cDNAs underwent 30 cycles for GDNF, NGF, VEGF and
β-actin, each one performed at 94°C for one minute, melt-
ing temperature (Tm) °C for 45 seconds and 72°C for 55
seconds (Table 1). After this treatment 10 μl of RT-PCR
products were separated by 1.5% agarose gel electrophor-
esis in Tris/Borate/EDTA (TBE) 0.5 × (Tris-base 0.089 m,
boric acid 0.089 m) containing 0.1 μg ml−1 of ethidium
bromide. Fragments of DNA were seen under ultraviolet
light. β-actin was used as an internal reference.
Immunofluorescence
After deparaffinization and rehydration, detection of TNFα,
IL-1β, GFAP and Iba1 was carried out after boiling in 0.1
M citrate buffer for one minute. Non-specific adsorption
was minimized by incubating the section in 2% (volume/
volume (vol/vol)) normal goat serum in PBS for 20 mi-
nutes. Sections were incubated with mouse monoclonal
anti-GFAP (1:100, vol/vol Santa Cruz Biotechnology
(Heidelberg, Germany), or with polyclonal rabbit anti-
TNFα (1:100, vol/vol Santa Cruz Biotechnology, Heidelberg,
Germany), or with rabbit anti-IL-1β (1:100, vol/vol Santa
Table 1 Specific primer sequences
Gene Forward primer (5′-- > 3′) Reverse primer (5′-- > 3′)
GDNF TCA CTG ACT TGG GTT TGG
GCT AT
TCA GAC GGC TGT TCT CAC
TCC TA
NGF GCA TCG AGT GAC TTT GGA
GC
GTA CGC CGA TCA AAA ACG
CA
VEGF TGG ATG TCT ACC AGC GAA
GC
ACA AGG CTC ACA GTG ATT
TT
β- actin CAT GAA GTG CGA CGT TGA
CA
CAC ATC TGC TGG AAG GTG
GA
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mouse monoclonal anti-Iba1 (1:100, vol/vol Santa Cruz
Biotechnology, Heidelberg, Germany) antibody in a hu-
midified oxygen and nitrogen chamber for over night at
37°C. Sections were incubated with secondary antibody
Fluorescein isothiocyanate (FITC)-conjugated anti-mouse
Alexa Fluor-488 antibody (1:2,000 vol/vol Molecular
Probes, Monza, Italy) and with TEXAS RED-conjugated
anti-rabbit Alexa Fluor-594 antibody (1:1000 in PBS, vol/
vol Molecular Probes, Monza, Italy) for one hour at 37°C.
For nuclear staining, 2 μg/ml 4′,6′-diamidino-2-phenylin-
dole (DAPI; Hoechst, Frankfurt, Germany) in PBS was
added. Sections were observed at 20× magnification using
a Leica DM2000 microscope (Leica, Milan, Italy). Optical
sections of fluorescence specimens were obtained using a
HeNe laser (543 nm), an ultraviolet laser (361 to 365 nm)
and an argon laser (458 nm) at a one-minute, two seconds
scanning speed with up to eight averages; 1.5 μm sections
were obtained using a pinhole of 250. Contrast and bright-
ness were established by examining the most brightly
labeled pixels and applying settings that allowed clear
visualization of structural details, while keeping the high-
est pixel intensities close to 200. The same settings were
used for all images obtained from the other samples that
had been processed in parallel. Digital images were
cropped and figure montages prepared using Adobe
Photoshop 7.0 (Adobe Systems; Palo Alto, California,
United States).
Materials
ATB-346 (2-(6-methoxy-napthalen-2-yl)-propionic acid 4-
thiocarbamoyl-phenyl ester), sodium naproxen and TBZ
(4-hydroxythiobenzamide) were provided by Antibe Ther-
apeutics Inc. (Toronto, Canada). Unless otherwise stated,
all other compounds were obtained from Sigma-Aldrich
Company Ltd. (Milan, Italy). All stock solutions were pre-
pared in non-pyrogenic saline (0.9% NaCl; Baxter, Italy) or
10% dimethyl sulfoxide (DMSO).
Statistical evaluation
Data are mean ± SEM. Data were analyzed using Graphpad
PRISM V (Graphpad Software Inc., La Jolla, California,
United States). Swing activity and time on platform wereanalyzed using two factor repeated measures analysis of
variance (RM ANOVA, group × time). Infarct area, lesion
volume and densitometric analysis data were analyzed by
ANOVA followed by a Bonferroni post-hoc test for multiple
comparisons. Histological score and percentage total tissue
area were analyzed by Student’s t-test. For all comparisons,
P <0.05 was considered to be significant. In the experiments
involving histology or immunohistochemistry, the figures
shown are representative of at least three experiments
performed on different experimental days on the tissue
sections collected from all the animals in each group.
Results
Effect of ATB-346 on IκBα degradation and NFκBp65
translocation
To investigate whether the cellular mechanism through
ATB-346 could attenuate inflammatory processes we
assessed Western blot analysis of the ipsilateral hemi-
sphere after TBI, using an IκBα and an NFκB-specific anti-
bodies. The results showed a basal expression of IκBα in
the brain from sham-mice (Figure 1A, see densitometry
analysis A1), while IκBα expression was significantly re-
duced in mice subject to TBI and TBZ administration, as
showed in Figure 1A and 1A1. Naproxen treatment
blunted the degradation of IκBα but ATB-346 was able to
significantly restore IκBα degradation (Figure 1A, see
densitometry analysis A1). Moreover, p65 subunit trans-
location was increased after TBI and TBZ injection in the
nuclear brain homogenates, compared with sham-group.
ATB-346 administration significantly reduced the trans-
location of p65 in nuclei compared to the TBI group
(Figure 1B, see densitometry analysis B1).
Effect of ATB-346 on iNOS and COX-2 expression
To determine the role of •NO produced during TBI, iNOS
expression was evaluated by Western blot analysis. A sig-
nificant increase in iNOS expression was observed in the
contused area from mice subjected to TBI and TBZ admin-
istration (Figure 1C, see densitometry analysis C1). Conse-
quently, naproxen reduced TBI-induced iNOS expression
(Figure 1C, see densitometry analysis C1); on the other
hand, a significant decrease in iNOS expression was ob-
served after ATB-346 treatment (Figure 1C see densitom-
etry analysis C1). Similarly, COX-2 expression was induced
by TBI and TBZ administration compared to the sham
group (Figure 1D, see densitometry analysis D1). Both
treatments with naproxen and ATB-346 lowered COX-2
expression (Figure 1D, see densitometry analysis D1).
Effect of ATB-346 on TNFα and IL-1β expression in astrocytes
after traumatic brain injury
To analyse the activation of astrocytes and cytokines ex-
pression, contused brain tissue at the impact site after
injury was double-stained with antibodies against GFAP
Figure 1 Effects of ATB-346 on Nuclear factor κB (NFκB) pathway and pro-inflammatory enzymes. Degradation of IκBα was significantly blocked
by Naproxen and ATB-346 treatment (A). Moreover, ATB-346 treatment resulted in an inhibition of nuclear translocation of p65 (B). Translocation of NFκB is
a critical step in the coupling of extracellular stimuli to the transcriptional activation of specific target genes. A significant increase in inducible nitric oxide
synthase (iNOS) and cyclooxygenase (COX)-2 (C and D, respectively) was observed in the injured area from TBI mice compared with the Sham mice.
ATB-346-treated mice had notably reduced expression of pro-inflammatory enzymes (C and D, respectively). Data show one representative blot from three
independent experiments with similar results. Mean ± SEM of four to five animals per group. One-way ANOVA, followed by Bonferroni’s multiple
comparison test. ***P <0.001 versus sham, ##P <0.01, ###P <0.001 versus TBI, °P <0.05 versus TBI + naproxen.
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1β (red; Figure 3). Brain sections revealed increased
astrogliosis (GFAP+ cells) in TBI and TBZ panels. More-
over, a marked co-localization of TNFα in GFAP+ cells
was present after TBI and TBZ administration (merged,
Figure 2). TNFα and IL-1β expressions were significantly
reduced by ATB-346 treatment (TBI + ATB-346 panels;
Figures 2 and 3).
Effect of ATB-346 on TNFα and IL-1β expression in
microglia after traumatic brain injury
To evaluate the microglia activation and its correlation
with cytokines expression, ipsilateral hemisphere to the
injury site were double-stained with antibodies against
Iba1 (green; Figures 4 and 5) and TNFα (red; Figure 4)or IL-1β (red; Figure 5). Microglial cells (Iba1- + cells)
expressed TNFα and IL-1β in TBI and TBZ panels
(Figures 4 and 5, respectively). There was an evident co-
localization of TNFα and Iba1 in TBI and TBZ panels
(merged, Figure 4). Considerable reductions in cytokines
expressions were evident in naproxen panels (Figures 4 and
5, respectively); however, ATB-346 reduced TNFα and IL-
1β expressions in microglia (Figures 4 and 5, respectively).
Effect of ATB-346 on mRNA levels of neurotrophic factors
To test whether ATB-346 modulates the levels of the
neurotrophic factors, we studied GDNF and NGF levels in
brain tissue using semi-quantitative RT–PCR analysis. A
significant decrease in GDNF (470 bp) and NGF (318 bp)
mRNA expression following TBI and TBZ administration
Figure 2 Effects of ATB-346 on tumor necrosis factor (TNF)α expression in glial fibrillary acidic protein (GFAP) positive cells. Brain tissue
was double-stained with antibodies against GFAP, green) and TNFα (red). The red spots indicate the co-localizations (merged). Brain sections
revealed increased astrogliosis (GFAP+ cells) in TBI and TBZ panels. Considerable GFAP immunoreactivity was present in TBI and TBZ panels. TNFα
expression was significantly reduced by ATB-346 treatment (TBI + ATB-346 panels) compared to naproxen treatment (TBI + naproxen panels).
All images were digitalized at 600 dpi.
Figure 3 Effects of ATB-346 on interleukin (IL)-1β expression in glial fibrillary acidic protein (GFAP) positive cells. Brain tissue was
double-stained with antibodies against GFAP (green) and IL-1β (red). Brain sections revealed increased astrogliosis (GFAP+ cells) in TBI and TBZ
panels. Considerable GFAP immunoreactivity was present in TBI and TBZ panels. IL-1β expression was significantly reduced after ATB-346
treatment (TBI + ATB-346 panels) respect to naproxen treatment (TBI + naproxen panels). All images were digitalized at 600 dpi.
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Figure 4 Effects of ATB-346 on tumor necrosis factor (TNF)α in ionized calcium binding adaptor molecule (Iba)1 positive cells. Brain
tissue was double-stained with antibodies against Iba1 (green) and TNFα (red). Microglial cells (Iba1+ cells) expressed TNFα in TBI and TBZ panels.
A considerable reduction of cytokine expression was present in naproxen panels; however, ATB-346 reduced notably TNFα expressions (TBI + ATB-346
panels). The red spots indicate the co-localizations (merged). All images were digitalized at 600 dpi.
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mRNA levels of both neurotrophic factors examined
(Figure 6A and B respectively, see densitometry analysis
A1 and B1 respectively).
Effect of ATB-346 on vascular components after traumatic
brain injury
To investigate whether ATB-346 could promote
normalization of the impaired neurovascular unit, we
observed VEGF level and eNOS expression. RT-PCR
showed a significant increase in VEGF (308 bp) mRNA
expression, and ATB-346 significantly increased its level
(Figure 6C, see densitometry analysis C1). Moreover, by
Western blot analysis we observed a significantly
increase in eNOS expression in the TBI group, and
ATB-346 upregulated its expression (Figure 6D, see
densitometry analysis D1).
Infarct outcome in ATB-346-treated mice after traumatic
brain injury
A histological examination of brain sections at the level of
the perilesional area, stained 24 hours after injury, revealed
significant damage in the TBI and TBI + TBZ groups, such
as prominent and thickened blood vessels, ischemic
changes and gliosis in the brain parenchyma (Figure 7B
and C respectively, see densitometry analysis F) compared
to sham mice (Figure 7A, see densitometry analysis F).Naproxen treatment attenuated the development of in-
flammation at 24 hours after TBI; ATB-346 significantly
reduced the degree of brain injury (Figure 7D and E re-
spectively, see densitometry analysis F).
Brain edema indicates pathology associated with en-
dothelial cell activation and endothelial dysfunction. To
evaluate the effect of ATB-346 on brain edema and infarc-
tions in the TBI and TBZ group, we performed TTC stain-
ing (Figure 8A). At 24 hours after TBI, ATB-346-treated
mice had a significantly smaller infarct area (Figure 8B)
and volume (Figure 8C).
Neurological deficits after ATB-346 administration
To investigate the relationship between neurological defi-
cits in the setting of TBI we used two different tests: the
EBST and the rotarod test, considered the most sensitive
vestibular motor test to assess motor function. The EBST
provided a motor asymmetry parameter and involved
handling the animal by its tail and recording the direction
of the biased body swings. The EBST consisted of 20 trials
with the number of swings ipsilateral and contralateral to
the ischemic hemisphere recorded and expressed in per-
centage to determine the biased swing activity. Mice were
tested seven days after TBI for both behavioral tests. CCI-
injured mice and TBZ-treated mice displayed a range of
impairments in locomotor tasks as showed in Figure 8D
and E, respectively. Both groups of animals that received
Figure 5 Effects of ATB-346 on interleukin (IL)-1β expression in ionized calcium binding adaptor molecule (Iba)1 positive cells. Brain
tissue was double-stained with antibodies against Iba1 (green) and IL-1β (red). Microglial cells (Iba1+ cells) expressed IL-1β in TBI and TBZ panels.
A considerable reduction of IL-1β expression was present in naproxen panels; at least, ATB-346 markedly reduced TNFα and IL-1β expressions
(ATB-346 panels). The red spots indicate the co-localizations (merged). All images were digitalized at 600 dpi.
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the EBST and rotarod tests compared with the TBI group
(Figure 8D and E, respectively).
Discussion
A number of animal models have been developed to induce
brain trauma. Of these the most commonly used are
weight-drop injury, fluid percussion injury (FPI) and CCI.
The use of TBI models has resulted in an increased under-
standing of the pathophysiology of TBI, including changes
in molecular and cellular pathways and neurobehavioral
outcomes. CCI models utilize a pneumatic pistol to laterally
deform the exposed dura and provide controlled impact
and quantifiable biomechanical parameters. This model
produces graded, reproducible brain injury. Dependent on
the severity of injury, CCI results in an ipsilateral injury
with cortical contusion, hemorrhage and blood-brain bar-
rier disruption. CCI injury reproduces changes reported in
clinical head injuries such as cortical contusion, brain
edema, subarachnoid hemorrhage, elevated intracerebral
pressure, reduced cortical perfusion, decreased cerebral
blood flow and neuro-endocrine and metabolic changes
[22]. The predominantly focal brain injury caused by CCI
makes this model to a useful tool for studying the patho-
physiology of the secondary processes induced by focal
brain injury. However, there is a lack of brain stem deform-
ation in this model and thus a low mortality rate.In recent years, H2S has been recognized as a funda-
mental signalling molecule that plays important roles in
exerting cytoprotective effects in the CNS, since it can
protect neurons and glia from oxidative stress [9,23].
H2S also exert many anti-inflammatory effects, including
inhibition of leukocyte-endothelial adherence, reduction
of edema formation [24,25] and inhibition of NFκB acti-
vation [26]. H2S is produced endogenously via enzymatic
activity, non-enzymatic pathways (such as reduction of
thiol-containing molecules), and is also released from
intracellular sulfur stores (sulfane sulfur). Cystathionine
β-synthase (CBS) is believed to be the critical enzyme
that produces H2S, resulting in the modulation of neuro-
logical function. H2S generated by cystathionine γ-lyase
(CSE) was next discovered as an important modulator of
vasorelaxation in smooth muscle. They separately coord-
inate with L-cysteine to produce H2S, L-serine and am-
monium. After the discovery of H2S as a potential
neurological and vasorelaxant signaling molecule, more
targets were expected to be found [27,28]. The enhanced
beneficial effects of ATB-346 over those of naproxen are
most likely attributable to the H2S release from the
former, and may be due to the neuroprotective and anti-
inflammatory properties of this gaseous mediator, acting
in a complimentary manner to the anti-inflammatory ef-
fects associated with inhibition of COX activity. Indeed,
the marked reduction of gastrointestinal toxicity of
Figure 6 RT–PCR analysis for GDNF, NGF and VEGF (A, B and C, respectively). ATB-346 treatment significantly increased both GDNF and NGF
mRNA expression compared to TBI (A and B, respectively). ATB-346 determined an important increase in VEGF mRNA expression (C). β-actin was
used as an internal control. mRNA was extracted and reverse-transcribed as described in the Methods section. Similar results were obtained in
four additional separate experiments. No bands were observed in the absence of cDNA. Western blot analysis showed that eNOS expression in
TBI mice was increased compared with sham mice (D), while ATB-346 upregulated its expression (D). A representative blot of homogenates
obtained from five animals per group is shown, and densitometry analysis of all animals is reported (A1 to D1). A P value of less than 0.05 was
considered significant. *P < 0.05, **P <0.01, ***P <0.001 versus sham, #P <0.05 versus TBI.
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mucosal protective and anti-inflammatory effects (for
example, inhibition of leukocyte adherence to vascular
endothelium) of the H2S released from this drug [29].
We observe a light beneficial effect of TBZ, the H2S-
releasing moiety of ATB-346, on several parameters. The
release of H2S from TBZ may not be as great as that
from an equimolar amount of ATB-346. Previous studies
have shown that TBZ alone releases very little H2S, but
when covalently linked to another drug, such as an
NSAID, considerably more H2S is released [30].Focal lesions to the brain display a characteristic
inflammatory response with infiltration of peripheral
immune cells after injury. These cells are believed to be
important because they contain and release a multitude
of inflammatory mediators associated with increased tis-
sue injury. Neutrophils peak approximately two days
post-TBI, and monocytes slightly later [31]. Leukocyte
homogenates from post-TBI patients display upregula-
tion of iNOS, COX-2 and nicotinamide adenine di-
nucleotide phosphate-oxidase; all enzymes involved in
producing the damaging neutrophilic oxidative burst
Figure 7 Histological examination of brain sections after 24 hours. Brain sections from TBI mice and TBZ-treated mice (B and C respectively,
see densitometry analysis F) demonstrated brain tissue injury and inflammatory cell infiltration. Naproxen treatment did not attenuate completely
the development of acute brain injury at one and six hours after TBI (D, see densitometry analysis F). On the contrary, ATB-346 treatment reduced
the degree of brain injury and the inflammatory cells infiltration (E, see densitometry analysis F). Figure is representative of at least three experiments
performed on different experimental days. ###P <0.001 versus TBI.
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inflammation, we have demonstrated here expression of
COX-2 and iNOS in the injured tissue after TBI, but
TBI-induced iNOS and COX-2 expression are signifi-
cantly lower in injured brains from ATB-346-treated
mice.
Post-TBI there is increased infiltration of neutrophils,
astrocytosis, edema and both pro- and anti-inflammatory
cytokines release. The major pro-inflammatory cytokines
released are IL-1β, IL-6 and TNFα. The anti-inflammatory
cytokines are IL-10 and transforming growth factor beta.
We demonstrate that increased microglial and astrocyte
activation is present 24 hours after TBI. Moreover, im-
munofluorescence staining showed increased TNFα and
IL-1β expression in astrocytes and microglia in TBI group.
ATB-346 treatment importantly reduced TNFα and IL-1β
expression in these glial cells. Apparently, ATB-346 might
enhance actual functional neuronal regeneration via inhi-
biting glial scar formation during TBI.
Neurotrophic factors have well-established roles in
survival, differentiation and function of CNS neurons.
Exogenous NGF, for example, plays a critical role in
neuronal plasticity and regenerative potential, as well as
the inhibition of neural apoptosis after TBI [33,34]. A
study found brain-derived neurotrophic factor,(BDNF)
and neurotrophin-3 (NT-3) support the survival of in-
jured CNS neurons in vitro and in vivo, induce neurite
outgrowth and increase the expression of key enzymes
for neurotransmitter synthesis [35]. GDNF is capable of
protecting against hippocampal neuronal death [36],attenuating brain swelling and reducing the lesion vol-
ume [37] after TBI. Our results visibly showed restored
GDNF and NGF levels after ATB-346 treatment, main-
taining their protective action.
VEGF, an angiogenic growth and survival factor for
endothelial cells that also exhibits neurotrophic and neu-
roprotective effects, has been implicated in neovasculari-
zation that precedes brain tissue repair and nerve
regeneration following brain injury and is required to
re-establish metabolic support [38]. VEGF is upregulated
during many pathological events, and it is induced in
astrocytes located in and surrounding edematous tissue
following brain contusion [39]. Our study showed that
ATB-346 significantly increased VEGF levels. Thus, it
could be hypothesized that ATB-346-facilitated the in-
crease in VEGF expression in the lesion area, resulting
in the secretion of VEGF from synthesizing cells and the
restoration of the neurovascular unit.
•NO is a key regulator of cerebral circulation by its
contribution to basal vascular tone that in vasculature is
mainly derived from eNOS. eNOS is predominantly
expressed by vessels endothelial cells and are also lo-
cated in Purkinje cell bodies in the cerebellar cortex,
olfactory bulb, dentate nucleus in granular layer and
hippocampal pyramidal cells and astrocytes surrounding
the cerebral blood vessels [40]. A recent paper showed
that eNOS is central after trauma for the maintenance of
blood flow in the injured cortex for at least 24 hours
after TBI; this is based on the observation that eNOS
knockout mice have lower cerebral blood flow at that
Figure 8 Effect of ATB-346 on brain edema, infarction and locomotor activity. Representative TTC stained brain section (four out of the six
consecutive sections from cranial to caudate region) corresponding to largest infraction from each group (A). Brain sections (2 mm thick) were
stained with TTC at 24 hours after TBI and show significant difference after ATB-346 treatment in terms of area (B) and volume (C) of infarctions.
The figures are representative of at least three experiments performed on different experimental days. TBI determined a range of impairments in
locomotor tasks, as showed by the EBST (D) and the rotarod test (E), after seven days. Both groups of animals that received naproxen or ATB-346
were significantly less impaired in EBST and rotarod tests compared with the TBI group. ATB-346-treated mice displayed significant improvement
in their behavioral performance as revealed by decreased biased swing activity in the EBST (D) and increased time on the rotating rod in the
rotarod test (E). Each data are expressed as mean ± SEM from N = four male CD mice for each group. A P value of less than 0.05 was considered
significant. ***P <0.001 versus sham, ###P <0.001 versus TBI.
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to this data, our results showed an evident increase in
eNOS expression 24 hours after TBI. The increase in
eNOS protein may represent either a protective or a rep-
arative response, since it has been reported that eNOS is
necessary to counteract posttraumatic cerebral hypoper-
fusion at 24 hours after CCI-TBI in mice [42]. There is
substantial evidence that H2S upregulates •NO produc-
tion in endothelial cells through the activation of eNOS,
inducing angiogenesis and improving functional outcome
[43-45]. Therefore, ATB 346 upregulates its expression, in-
creasing functional protein expression and augmentation
of cerebral blood flow, also in the brain. Furthermore,
treatment with ATB-346 results in a significant reduction
in inflammation and it is also accompanied by a detectablehistological improvement of TBI. As shown in our recent
paper, ATB-346 can markedly accelerate recovery of
motor function in mice subjected to SCI [12]. Here, in a
different model of neurotrauma, we confirmed that ATB-
346 significantly improved the latency compared to the
naproxen group, indicated as a mediator of the mechan-
ism to promote recovery and to enhance the repair mech-
anism. In the present study, post-TBI administration of
ATB-346 not only facilitated functional recovery, but also
reduced tissue damage within hours following injection.
The ameliorating effect of ATB-346 at tissue level was
further corroborated by its ability to reduce the extent of
neurodegeneration. The neuroprotective basis for these
actions seems to be dependent on the H2S-releasing moi-
ety of ATB-346, as also stated in a recent paper [46].
Figure 9 Schematic representation of the method outlined in this experiment and results obtained.
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produce the same ‘restorative’ effect on neurotrophic fac-
tors as seen with ATB-346 suggests that both suppression
of COX and delivery of H2S is required to achieve the ob-
served effect. The properties of this compound are sum-
marized in Figure 9. In May 2014 Antibe Therapeutics has
announced the submission of a clinical trial application to
Health Canada for ATB-346.
Conclusions
The need for developing new therapeutics for TBI treat-
ment and the current lack of specific therapy for this in-
dication underscore the importance of identification and
characterization of novel neuroprotective compounds.
Released-H2S may account for the absence of deleterious
gastric effects, thus making of ATB-346 a potentially
useful therapeutic alternative to traditional naproxen for
the management of secondary damage following CNSdiseases, counteracting behavioral changes and inflam-
matory process.Abbreviations
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